Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Medincell has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The portfolio's current prosecution is limited to 1 distinct examiner working within a distinct art unit. This indicates a singular point of administrative contact for the company's active patent applications. The concentration of matters within a specific technical field suggests a focused approach to the current phase of portfolio development.
VISHNYAKOVA, ELENA VLADIMIROVNA is the busiest examiner for the portfolio, handling the only pending office action. Because this examiner manages the current workload, they oversee the office action responses for the company. Strategy should be tailored to the specific requirements and historical examination patterns of this examiner. Practitioners must address the technical requirements of the identified art unit to move the pending application toward allowance. The singular nature of the current prosecution allows for a dedicated focus on the feedback provided by this specific examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VISHNYAKOVA, ELENA VLADIMIROVNA | 1 | 68.3% | +46.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17952044 | BIODEGRADABLE DRUG DELIVERY COMPOSITIONS | VISHNYAKOVA, ELENA VLADIMIROVNA | — |
| Art Unit | Apps |
|---|---|
| 1600 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17952044 | BIODEGRADABLE DRUG DELIVERY COMPOSITIONS | VISHNYAKOVA, ELENA VLADIMIROVNA | 1600 | §112DP | Final Rejection | — | Pending | Sep 23, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMedincell has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Elena Vladimirovna Vishnyakova has the most, with 1 of Medincell's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
